Krzysztof Jaworski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Krzysztof Jaworski has a total of 115 co-authors. Here are the top co-authors by number of shared publications:
Ilona Kowalik
4 shared publicationsJerzy Windyga
Institute of Hematology and Transfusion Medicine, Warsaw, Department of Hemostasis Disorders and Internal Medicine, Poland
4 shared publicationsMariusz Pytkowski
4 shared publicationsRafal Dabrowski
4 shared publicationsRafał Dąbrowski
Department of Radiology, National Institute of Cardiology, Warszawa, Poland
4 shared publicationsBohdan Firek
Department of Coronary Artery Disease and Cardiac Rehabilitation, National Institute of Cardiology, Warsaw, Poland
3 shared publications
Latest Publications
- Open Access
- 1 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 492
From Diagnosis to Treatment of Arrhythmic Mitral Valve Prolapse and Mitral Annular Disjunction
Mitral valve prolapse (MVP) and mitral annular disjunction (MAD) are common comorbidities that can lead to serious cardiac arrhythmias and sudden cardiac death (SCD). Arrhythmic MVP is characterized by the presence of MVP with frequent (over 5% ventricular extra beats) and/or complex ventricular arrhythmias, such as ventricular tachycardia (VT), non-sustained VT, or ventricular fibrillation in the absence of other causes of arrhythmia, e.g., post-infarction scar, recent ischemia, channelopathy, or cardiomyopathy. The mechanisms of the development of serious cardiac arrhythmias in patients with MVP and MAD are not fully understood. Arrhythmic MVP may be an indication for cardioverter defibrillator implantation. Considering the increased risk of SCD in this group of patients, the pathophysiology of this valvular dysfunction and characteristic deviations in diagnostic tests that indicate a higher risk of SCD are presented. The issue of tailored risk stratification in individual patients is crucial.
- 1 October 2026
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 13 (10) , 492
Open AccessFrom Diagnosis to Treatment of Arrhythmic Mitral Valve Prolapse and Mitral Annular Disjunction
Mitral valve prolapse (MVP) and mitral annular disjunction (MAD) are common comorbidities that can lead to serious cardiac arrhythmias and sudden cardiac death (SCD). Arrhythmic MVP is characterized by the presence of MVP with frequent (over 5% ventricular extra beats) and/or complex ventricular arrhythmias, such as ventricular tachycardia (VT), non-sustained VT, or ventricular fibrillation in the absence of other causes of arrhythmia, e.g., post-infarction scar, recent ischemia, channelopathy, or cardiomyopathy. The mechanisms of the development of serious cardiac arrhythmias in patients with MVP and MAD are not fully understood. Arrhythmic MVP may be an indication for cardioverter defibrillator implantation. Considering the increased risk of SCD in this group of patients, the pathophysiology of this valvular dysfunction and characteristic deviations in diagnostic tests that indicate a higher risk of SCD are presented. The issue of tailored risk stratification in individual patients is crucial.
- 22 August 2026
- Published by Elsevier in Heart Rhythm
Exercise stress testing in the prediction of sudden cardiac arrest associated with mitral valve prolapse
- 22 August 2026
- Published by Elsevier in Heart Rhythm
Exercise stress testing in the prediction of sudden cardiac arrest associated with mitral valve prolapse
- Open Access
- 15 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Incidence and type of recurrent ventricular arrhythmia in patients with arrhythmic mitral valve prolapse and implantable cardioverter defibrillator for secondary prevention
Aims: Mitral valve prolapse (MVP) is a common valvular disorder associated with ventricular arrhythmias (VAs) in a subgroup of patients, known as arrhythmic MVP (AMVP). Arrhythmic MVP patients with malignant VAs typically receive an implantable cardioverter-defibrillator (ICD) for secondary prevention. However, data regarding the incidence of appropriate ICD therapy and the type of arrhythmia recurrence in this population remain scarce. This study aimed to evaluate the incidence of appropriate ICD therapies and type of arrhythmia recurrence in AMVP patients with an ICD implanted for secondary prevention. Methods and results: A systematic literature search was conducted in PubMed/MEDLINE and EMBASE databases until January 2025. Studies reporting the incidence of appropriate ICD therapy in AMVP patients were included. A total of 9 studies met the inclusion criteria, resulting in 166 AMVP patients with ICDs for secondary prevention. The mean age was 41.8 years, with 55.8% of patients being female. Over a weighted mean follow-up of 4.9 ± 3.1 years, 34.9% [95% confidence interval (CI): 28.1–42.5] of the patients experienced recurrence of VA. The pooled incidence of appropriate ICD therapies during follow-up was 8.1 per 100 person-years (95% CI: 5.6–10.5, I2: 11.7%). Regarding the type of arrhythmic recurrence, the majority of arrhythmias (53.8%, 95% CI: 44.3–63.0%) were in the form of ventricular fibrillation or polymorphic ventricular tachycardia (VT), while the remaining arrhythmias were reported as monomorphic VT. Among 67 ventricular arrhythmic episodes reported in 7 studies with available data, 65 required shock therapy, corresponding to a shock proportion of 97.0% (95% CI: 89.6–99.6%). Conclusion: Arrhythmic MVP patients with ICDs for secondary prevention exhibit a high risk of recurrent arrhythmias, with recurrences in the form of polymorphic VA occurring in more than half of the cases. PROSPERO registration number: CRD42024588610
- 15 May 2026
- Published by Oxford University Press (OUP) in EP Europace
- Vol. 28 (6)
Open AccessIncidence and type of recurrent ventricular arrhythmia in patients with arrhythmic mitral valve prolapse and implantable cardioverter defibrillator for secondary prevention
Aims: Mitral valve prolapse (MVP) is a common valvular disorder associated with ventricular arrhythmias (VAs) in a subgroup of patients, known as arrhythmic MVP (AMVP). Arrhythmic MVP patients with malignant VAs typically receive an implantable cardioverter-defibrillator (ICD) for secondary prevention. However, data regarding the incidence of appropriate ICD therapy and the type of arrhythmia recurrence in this population remain scarce. This study aimed to evaluate the incidence of appropriate ICD therapies and type of arrhythmia recurrence in AMVP patients with an ICD implanted for secondary prevention. Methods and results: A systematic literature search was conducted in PubMed/MEDLINE and EMBASE databases until January 2025. Studies reporting the incidence of appropriate ICD therapy in AMVP patients were included. A total of 9 studies met the inclusion criteria, resulting in 166 AMVP patients with ICDs for secondary prevention. The mean age was 41.8 years, with 55.8% of patients being female. Over a weighted mean follow-up of 4.9 ± 3.1 years, 34.9% [95% confidence interval (CI): 28.1–42.5] of the patients experienced recurrence of VA. The pooled incidence of appropriate ICD therapies during follow-up was 8.1 per 100 person-years (95% CI: 5.6–10.5, I2: 11.7%). Regarding the type of arrhythmic recurrence, the majority of arrhythmias (53.8%, 95% CI: 44.3–63.0%) were in the form of ventricular fibrillation or polymorphic ventricular tachycardia (VT), while the remaining arrhythmias were reported as monomorphic VT. Among 67 ventricular arrhythmic episodes reported in 7 studies with available data, 65 required shock therapy, corresponding to a shock proportion of 97.0% (95% CI: 89.6–99.6%). Conclusion: Arrhythmic MVP patients with ICDs for secondary prevention exhibit a high risk of recurrent arrhythmias, with recurrences in the form of polymorphic VA occurring in more than half of the cases. PROSPERO registration number: CRD42024588610
- 8 May 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 152, 106920
Hypertension and blood pressure profiles in patients with acute intermittent porphyria: a prospective case-control study
- 8 May 2026
- Published by Elsevier in European Journal of Internal Medicine
- Vol. 152, 106920
Hypertension and blood pressure profiles in patients with acute intermittent porphyria: a prospective case-control study
- Open Access
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
The edge-to-edge repair of the iatrogenic torrential tricuspid regurgitation complicating transvenous pacemaker lead extraction: a case series
Background: New tricuspid regurgitation (TR) or worsening of baseline pathology may appear after transvenous pacemaker lead extraction (TLE). In case of severe TR induced by TLE, surgical correction might be required. However, the patients in whom TLE is performed are not always appropriate candidates for open-heart intervention. Case Summary: Herein, we present four patients with iatrogenic TR significantly increased to severe-torrential grade after TLE, who were disqualified from surgery. In three cases, the regurgitation was associated with an avulsion of the papillary muscles or chordae tendineae. In one case, it was likely due to the perforation of the tricuspid leaflet during TLE. Patients were treated with transcatheter tricuspid edge-to-edge repair (T-TEER), in three cases successfully. Discussion: Percutaneous repair of TLE-related TR is feasible and may be a valuable therapeutic option in patients with prohibitive surgical risk. One of the most important factors leading to a T-TEER procedural success is the accurate assessment of the tricuspid regurgitation mechanism. In the fourth case, identification of the underlying regurgitation cause was limited by the image quality in the transoesophageal examination.
- 2 March 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Case Reports
- Vol. 10 (3)
Open AccessThe edge-to-edge repair of the iatrogenic torrential tricuspid regurgitation complicating transvenous pacemaker lead extraction: a case series
Background: New tricuspid regurgitation (TR) or worsening of baseline pathology may appear after transvenous pacemaker lead extraction (TLE). In case of severe TR induced by TLE, surgical correction might be required. However, the patients in whom TLE is performed are not always appropriate candidates for open-heart intervention. Case Summary: Herein, we present four patients with iatrogenic TR significantly increased to severe-torrential grade after TLE, who were disqualified from surgery. In three cases, the regurgitation was associated with an avulsion of the papillary muscles or chordae tendineae. In one case, it was likely due to the perforation of the tricuspid leaflet during TLE. Patients were treated with transcatheter tricuspid edge-to-edge repair (T-TEER), in three cases successfully. Discussion: Percutaneous repair of TLE-related TR is feasible and may be a valuable therapeutic option in patients with prohibitive surgical risk. One of the most important factors leading to a T-TEER procedural success is the accurate assessment of the tricuspid regurgitation mechanism. In the fourth case, identification of the underlying regurgitation cause was limited by the image quality in the transoesophageal examination.
- Open Access
- 26 November 2025
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 84 (4) , 561-562
Giant right atrial mobile thrombus detected shortly after pacemaker implantation: Clinical implications
A 64-year-old man with a history of paroxysmal atrial fibrillation was admitted to the hospital due to second degree Mobitz type II (2:1 and 3:1) atrioventricular block (Figure 1A). The patient denied any symptoms and declared systematic treatment with dabigatran 110 mg bis in die (the reduced dose for unknown reasons). Pacemaker implantation was performed without complications. Two doses of dabigatran were skipped in periprocedural period. The routine predischarge transthoracic echocardiographic examination performed two days later showed right atrial mass which was moving into and out of the right ventricle (Figure 1B; Supplementary material, Video S1). The size (96 mm of length and 8 mm of width), shape and coincidence with
- 26 November 2025
- Published by Polskie Towarzystwo Kardiologiczne in Polish Heart Journal
- Vol. 84 (4) , 561-562
Open AccessGiant right atrial mobile thrombus detected shortly after pacemaker implantation: Clinical implications
A 64-year-old man with a history of paroxysmal atrial fibrillation was admitted to the hospital due to second degree Mobitz type II (2:1 and 3:1) atrioventricular block (Figure 1A). The patient denied any symptoms and declared systematic treatment with dabigatran 110 mg bis in die (the reduced dose for unknown reasons). Pacemaker implantation was performed without complications. Two doses of dabigatran were skipped in periprocedural period. The routine predischarge transthoracic echocardiographic examination performed two days later showed right atrial mass which was moving into and out of the right ventricle (Figure 1B; Supplementary material, Video S1). The size (96 mm of length and 8 mm of width), shape and coincidence with
- 30 July 2025
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 39 (1) , 1-14
Multiparametric Approach to Arrhythmic Mitral Valve Prolapse: Novel and Recognized Markers of Increased Sudden Cardiac Arrest Risk
- 30 July 2025
- Published by Elsevier in Journal of the American Society of Echocardiography
- Vol. 39 (1) , 1-14
Multiparametric Approach to Arrhythmic Mitral Valve Prolapse: Novel and Recognized Markers of Increased Sudden Cardiac Arrest Risk
- 7 January 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (10) , 2447-2456
Mitral valve prolapse in sudden cardiac arrest survivors: Coincidence or causal relationship?
- 7 January 2025
- Published by Elsevier in Heart Rhythm
- Vol. 22 (10) , 2447-2456
Mitral valve prolapse in sudden cardiac arrest survivors: Coincidence or causal relationship?
- Open Access
- 8 August 2024
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 134 (7-8)
Cardiovascular abnormalities in patients with acute intermittent porphyria: the AIPRACUS study
DOI: 10.20452/pamw.16820, Published online: August 08, 2024, Authors: Krzysztof Jaworski1, Robert Wasilewski2, Jerzy Windyga2, Andrzej Januszewicz3, Hanna Szwed1, Rafał Dąbrowski1
- 8 August 2024
- Published by "Medycyna Praktyczna" Spolka Jawna in Polish Archives of Internal Medicine
- Vol. 134 (7-8)
Open AccessCardiovascular abnormalities in patients with acute intermittent porphyria: the AIPRACUS study
DOI: 10.20452/pamw.16820, Published online: August 08, 2024, Authors: Krzysztof Jaworski1, Robert Wasilewski2, Jerzy Windyga2, Andrzej Januszewicz3, Hanna Szwed1, Rafał Dąbrowski1
- Open Access
- 28 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3164
Troponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA-Related Dilated Cardiomyopathy
Background: LMNA-related dilated cardiomyopathy (LMNA-DCM) caused by mutations in the lamin A/C gene (LMNA) is one of the most common forms of hereditary DCM. Due to the high risk of mutation transmission to offspring and the high incidence of ventricular arrhythmia and sudden death even before the onset of heart failure symptoms, it is very important to identify LMNA-mutation carriers. However, many relatives of LMNA-DCM patients do not report to specialized centers for clinical or genetic screening. Therefore, an easily available tool to identify at-risk subjects is needed. Methods: We compared two cohorts of young, asymptomatic relatives of DCM patients who reported for screening: 29 LMNA mutation carriers and 43 individuals from the control group. Receiver operating characteristic (ROC) curves for potential indicators of mutation carriership status were analyzed. Results: PR interval, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity cardiac troponin T (hscTnT) serum levels were higher in the LMNA mutation carrier cohort. Neither group differed significantly with regard to creatinine concentration or left ventricular ejection fraction. The best mutation carriership discriminator was hscTnT level with an optimal cut-off value at 5.5 ng/L, for which sensitivity and specificity were 86% and 93%, respectively. The median hscTnT level was 11.0 ng/L in LMNA mutation carriers vs. p < 0.001. Conclusions: Wherever access to genetic testing is limited, LMNA mutation carriership status can be assessed reliably using the hscTnT assay. Among young symptomless relatives of LMNA-DCM patients, a hscTnT level >5.5 ng/L strongly suggests mutation carriers.
- 28 May 2024
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 13 (11) , 3164
Open AccessTroponin T Assessment Allows for Identification of Mutation Carriers among Young Relatives of Patients with LMNA-Related Dilated Cardiomyopathy
Background: LMNA-related dilated cardiomyopathy (LMNA-DCM) caused by mutations in the lamin A/C gene (LMNA) is one of the most common forms of hereditary DCM. Due to the high risk of mutation transmission to offspring and the high incidence of ventricular arrhythmia and sudden death even before the onset of heart failure symptoms, it is very important to identify LMNA-mutation carriers. However, many relatives of LMNA-DCM patients do not report to specialized centers for clinical or genetic screening. Therefore, an easily available tool to identify at-risk subjects is needed. Methods: We compared two cohorts of young, asymptomatic relatives of DCM patients who reported for screening: 29 LMNA mutation carriers and 43 individuals from the control group. Receiver operating characteristic (ROC) curves for potential indicators of mutation carriership status were analyzed. Results: PR interval, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and high-sensitivity cardiac troponin T (hscTnT) serum levels were higher in the LMNA mutation carrier cohort. Neither group differed significantly with regard to creatinine concentration or left ventricular ejection fraction. The best mutation carriership discriminator was hscTnT level with an optimal cut-off value at 5.5 ng/L, for which sensitivity and specificity were 86% and 93%, respectively. The median hscTnT level was 11.0 ng/L in LMNA mutation carriers vs. p < 0.001. Conclusions: Wherever access to genetic testing is limited, LMNA mutation carriership status can be assessed reliably using the hscTnT assay. Among young symptomless relatives of LMNA-DCM patients, a hscTnT level >5.5 ng/L strongly suggests mutation carriers.